Hims & Hers Health, Inc. (HIMS)
| Market Cap | 4.49B |
| Revenue (ttm) | 959.40M |
| Net Income (ttm) | -2.35M |
| Shares Out | 206.41M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | 112.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,447,173 |
| Open | 23.72 |
| Previous Close | 23.25 |
| Day's Range | 21.36 - 24.24 |
| 52-Week Range | 5.65 - 25.74 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | 19.33 (-11.21%) |
| Earnings Date | Aug 5, 2024 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
In 2023, HIMS's revenue was $872.00 million, an increase of 65.49% compared to the previous year's $526.92 million. Losses were -$23.55 million, -64.15% less than in 2022.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for HIMS stock is "Buy." The 12-month stock price forecast is $19.33, which is a decrease of -11.21% from the latest price.
News
Red-Hot Prescription Stock Flashing A Bullish Signal
Prescription stock Hims & Hers Health (HIMS) is down 2.8% to trade at $22.45 today, and last week suffered a 10.6% drawdown. The upside is that the pullback has HIMS brushing up against a historically...
Pharmaceutical Industry Chief Kåre Schultz Joins Hims & Hers Board
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Kåre Schultz to the company's Board o...
Hims & Hers to Announce Second Quarter 2024 Financial Results on August 5, 2024
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. ("Hims & Hers") (NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter financial results af...
Don't place your hopes on Hims & Hers GLP-1 business, says Jim Cramer
'Mad Money' host Jim Cramer takes a look at Hims & Hers to assess if its a good healthcare move for your portfolio.
Jim Cramer on Hims & Hers Health stock: 'I bet the business stays strong'
CNBC's Jim Cramer gave his take on the Hims & Hers Health, a digital health and wellness platform, saying it might be worth opening a position in the stock now that it's pulled back somewhat from its ...
Hims & Hers shares plunge 12% amid allegations of GLP-1 drug sourcing from ‘shady supplier'
Roughly a month after announcing that it would offer GLP-1 injectable weight-loss drugs comparable to the popular drugs Ozempic and Mounjaro, Hims & Hers Health shares are taking a beating after a new...
Hims & Hers shares fall on Hunterbrook report that GLP-1 drugs come from 'shady supplier'
Sam Koppelman, Hunterbrook Media publisher and co-founder, joins 'Closing Bell Overtime' to talk its report that Hims & Hers' GLP-1 offering is a 'knockoff' drug form 'shady supplier'.
Hims & Hers rolls out weight-loss shots much cheaper than Ozempic, Wegovy
Health and wellness company Hims & Hers announced Monday that it is introducing injectable weight-loss drugs at a fraction of the cost of Ozempic and Wegovy.
Hims & Hers Health stock price nears record high on news that it will offer GLP-1 weight-loss drugs amid shortages
Hims & Hers Health got a shot in the arm this week that sent its share prices to near all-time highs.
Celebrity Fitness Trainer Jillian Michaels weighs in on Hims & Hers offering weight-loss drugs
Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tune in Monday through Friday at 7 p.m.
Dr. Craig Primack talks Hims & Hers launching its own GLP-1 offering as demand rises
Dr. Craig Primack, Hims & Hers SVP of Weight Management, joins 'Closing Bell Overtime' to talk the company offering a GLP-1 drug through its platform.
Hims & Hers Health Stock Jumps Nearly 28% on Plans to Offer GLP-1 Weight-Loss Drugs
Shares of Hims & Hers Health (HIMS) surged close to 28% Monday after the telehealth company said it would begin offering GLP-1 injections as part of its weight-loss package of drugs.
Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative To Wegovy
Shares of telehealth company Hims & Hers Health closed at a three-year high Monday after the company announced a weight-loss treatment starting at $199 a month that will compete with Novo Nordisk's We...
Three-Stock Lunch: Microsoft, Johnson Controls and Hims & Hers Health
David Trainer, New Constructs CEO, joins 'Power Lunch' to discuss plays for three stocks: Microsoft, Johnson Controls, and Hims & Hers Health.
Hims & Hers Health says it will offer compounded GLP-1 drugs, despite FDA warnings
Hims & Hers Health Inc.'s stock HIMS, +32.81% jumped more than 30% Monday morning after the health and wellness platform said it would offer compounded GLP-1 drugs — products that the Food and Drug Ad...
The case for the overvalued Hims & Hers stock
Hims & Hers Health (NYSE: HIMS) stock price is doing well, helped by its strong growth and demand for its core products. It soared by over 30% this year and by more than 112% this year.
Hims & Hers Health adds compounded GLP-1 injections to weight loss program
The GLP-1 market has faced supply constraints in recent months as the drugs like Ozempic and Wegovy skyrocket in popularity.
Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto Customers
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc., the leading health and wellness platform, today announced the addition of GLP-1 injections to its comprehensive weight loss portfolio, giving ...
Hims & Hers Welcomes Anja Manuel, Foreign Policy Expert, Domestic Regulations Advisor, and Former Diplomat to its Board of Directors
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Anja Manuel to the company's Board of...
3-Stock Lunch: PLTR, HIMS & GPS
Courtney Garcia, Payne Capital Management senior wealth advisor, to discuss investment plays for three stocks including; Palantir, Hims and Hers Health Inc. and Gap.
Him & Hers earnings beat estimates, CEO weighs in on campus protests
CNBC's Andrew Ross Sorkin reports on the latest news.
Hims & Hers shares rally as forecast bumped higher and more profitability said to be ahead
Shares of Hims & Hers Health Inc. rose after hours on Monday after the online wellness platform bumped its full-year sales forecast higher, following sharp increases in subscribers and profits during ...
Hims & Hers Health, Inc. Reports First Quarter 2024 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the first quarter...
Hims & Hers CEO walks back praise for anti-Israel protesters after stock drops
Hims & Hers founder and CEO Andrew Dudum said Sunday that his earlier comments praising anti-Israel protesters on college campuses were "misconstrued by some."
Hims & Hers stock slides after CEO's praise for anti-Israel protesters
Hims & Hers Health stock declined Friday by about 8% after CEO Andrew Dudum's praise for anti-Israel campus protesters in a social media post last week.